Photo from wikipedia
Limited data exist on the safety of using anti–human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients… Click to show full abstract
Limited data exist on the safety of using anti–human epidermal growth factor receptor 2 (HER2) targeted agents during pregnancy. To date, only retrospective studies have assessed the prognosis of patients with a pregnancy after prior early breast cancer, with no data in HER2‐positive patients.
Keywords:
early breast;
factor receptor;
human epidermal;
growth factor;
cancer;
epidermal growth
Journal Title: Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!